MGTX

8.0001.72%
SN

Stuart Naylor

Chief Scientific Officer of Ophthalmology

Dr. Stuart Naylor, Ph.D., is Chief Scientific Officer of Ophthalmology of MeiraGTx Holdings plc from May 2026. Dr. Naylor was Chief Development Officer of MeiraGTx Holdings plc from May 10, 2019 to May 2026. He served as the Chief Scientific Officer of Oxford BioMedica PLC from July 2008 to June 6, 2013. Dr. Naylor served as Senior Vice President of Research & Development of Oxford BioMedica PLC. He joined Oxford from the Institute of Cancer Research and is major figure in the technical development of its oncology programmes as well as pioneering Oxford BioMedica's ocular products, including RetinoStat(R) for the treatment of age-related macular degeneration and diabetic retinopathy and StarGen(TM) for the treatment of Stargardt disease. Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, a gene therapy company since 2008 until 2013. He served as a Director of MeiraGTx Holdings plc since April 2015 until May 10, 2019. He served as Director of Oxford BioMedica PLC from July 1, 2008 to June 6, 2013. From June 2013 to April 2015, Dr. Naylor served as managing director of Coltivare Ltd. His career has covered many aspects of tumour biology from its molecular basis to the clinic. From April 2015 to April 2016, Dr. Naylor was Chief Executive Officer of Athena Vision. He established an international reputation at two world class cancer institutes, the Imperial Cancer Research Fund and the Institute of Cancer Research. He has published numerous primary and review articles notably in the field of cytokine research and has an extensive network of collaborators in many aspects of basic research and clinical oncology. Dr. Naylor has a B.S.C. in microbiology and virology from the University of Warwick, an M.S. in Immunology from Kings College London and a Ph.D. from the Imperial Cancer Research Fund laboratory studying ovarian cancer and cytokine biology.

Positions